Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer

References

• Nicholson RI, Johnston SR. Endocrine therapy – current benefits and limitations. Breast Cancer Res. Treat.93(Suppl. 1), S3–S10 (2005).
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V, Bengala C. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. Clin. Breast Cancer7(11), 841–849 (2007).
   PubMedGoogle Scholar
• Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R. Response and resistance to the endocrine prevention of breast cancer. Adv. Exp. Med. Biol.617, 201–211 (2008).
   PubMedGoogle Scholar
• Nicholson RI, Hutcheson IR, Jones HE et al. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev. Endocr. Metab. Disord.8(3), 241–253 (2007).
   PubMedGoogle Scholar
• Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev.29(2), 217–233 (2008).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer11(4), 623–641 (2004).
   PubMed Web of Science ®Google Scholar
• Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib (‘Iressa’, ZD1839). Clin. Exp. Metastasis21(3), 201–212 (2004).
   PubMed Web of Science ®Google Scholar
• Hiscox S, Morgan L, Green T, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat.1–12 (2005).
   Google Scholar
• Hiscox S, Jordan NJ, Smith C et al. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res. Treat.115(1), 57–67 (2009).
   PubMed Web of Science ®Google Scholar
• Martin GS. The road to Src. Oncogene23(48), 7910–7917 (2004).
   PubMed Web of Science ®Google Scholar
• Martins-Green M, Bixby JL, Yamamoto T, Graf T, Sudol M. Tissue specific expression of Yrk kinase: implications for differentiation and inflammation. Int. J. Biochem. Cell Biol.32(3), 351–364 (2000).
   PubMedGoogle Scholar
• Wong KS, Proulx K, Rost MS, Sumanas S. Identification of vasculature-specific genes by microarray analysis of Etsrp/Etv2 overexpressing zebrafish embryos. Dev. Dyn.238(7), 1836–1850 (2009).
   PubMedGoogle Scholar
• Gomez GA, Veldman MB, Zhao Y, Burgess S, Lin S. Discovery and characterization of novel vascular and hematopoietic genes downstream of Etsrp in zebrafish. PLoS One4(3), e4994 (2009).
   PubMedGoogle Scholar
• Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal.22(8), 1175–1184 (2010).
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett.543(1–3), 76–80 (2003).
   PubMed Web of Science ®Google Scholar
• Chong YP, Mulhern TD, Cheng HC. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK) – endogenous negative regulators of Src-family protein kinases. Growth Factors23(3), 233–244 (2005).
   PubMed Web of Science ®Google Scholar
• Chong YP, Mulhern TD, Zhu HJ et al. A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity. J. Biol. Chem.279(20), 20752–20766 (2004).
   PubMed Web of Science ®Google Scholar
• Yagi R, Waguri S, Sumikawa Y et al. C-terminal Src kinase controls development and maintenance of mouse squamous epithelia. EMBO J.26(5), 1234–1244 (2007).
   PubMed Web of Science ®Google Scholar
• Di Stefano P, Damiano L, Cabodi S et al. p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO J.26(12), 2843–2855 (2007).
   PubMedGoogle Scholar
• Sirvent A, Benistant C, Pannequin J et al. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene29(9), 1303–1315 (2010).
   PubMedGoogle Scholar
• McShan GD, Zagozdzon R, Park SY et al. Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration. Int. J. Oncol.21(1), 197–205 (2002).
   PubMedGoogle Scholar
• Stover DR, Furet P, Lydon NB. Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J. Biol. Chem.271(21), 12481–12487 (1996).
   PubMed Web of Science ®Google Scholar
• Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol. Cell Biol.25(15), 6391–6403 (2005).
   PubMed Web of Science ®Google Scholar
• Sun Y, McGarrigle D, Huang XY. When a G protein-coupled receptor does not couple to a G protein. Mol. Biosyst.3(12), 849–854 (2007).
   PubMedGoogle Scholar
• Patwardhan P, Resh MD. Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol. Cell Biol.30(17), 4094–4107 (2010).
   PubMed Web of Science ®Google Scholar
• Irby RB, Mao W, Coppola D et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet.21(2), 187–190 (1999).
   PubMed Web of Science ®Google Scholar
• Sugimura M, Kobayashi K, Sagae S et al. Mutation of the SRC gene in endometrial carcinoma. Jpn J. Cancer Res.91(4), 395–398 (2000).
   PubMedGoogle Scholar
• Wang NM, Yeh KT, Tsai CH, Chen SJ, Chang JG. No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese. Cancer Lett.150(2), 201–204 (2000).
   PubMedGoogle Scholar
• Laghi L, Bianchi P, Orbetegli O, Gennari L, Roncalli M, Malesci A. Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. Br. J. Cancer84(2), 196–198 (2001).
   PubMed Web of Science ®Google Scholar
• Guarino M. Src signaling in cancer invasion. J. Cell Physiol.223(1), 14–26 (2010).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature375(6532), 577–581 (1995).
   PubMed Web of Science ®Google Scholar
• Fleming RY, Ellis LM, Parikh NU, Liu W, Staley CA, Gallick GE. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery122(2), 501–507 (1997).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Staley CA, Liu W et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem.273(2), 1052–1057 (1998).
   PubMed Web of Science ®Google Scholar
• Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1α-expression under normoxia. J. Biol. Chem.277(45), 42919–42925 (2002).
   PubMedGoogle Scholar
• Niu G, Briggs J, Deng J et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells. Mol. Cancer Res.6(7), 1099–1105 (2008).
   PubMed Web of Science ®Google Scholar
• Lee HY, Lee T, Lee N et al. Src activates HIF-1α; not through direct phosphorylation of HIF-1α-specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway. Carcinogenesis DOI: 10.1093/carcin/bgr034 (2011) (Epub ahead of print).
   Google Scholar
• Chou MT, Anthony J, Bjorge JD, Fujita DJ. The von Hippel-Lindau tumor suppressor protein is destabilized by Src: implications for tumor angiogenesis and progression. Genes Cancer1(3), 225–238 (2010).
   PubMedGoogle Scholar
• Gray MJ, Zhang J, Ellis LM et al. HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene24(19), 3110–3120 (2005).
   PubMed Web of Science ®Google Scholar
• Agarwal A, Tressel SL, Kaimal R et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res.70(14), 5880–5890 (2010).
   PubMed Web of Science ®Google Scholar
• Hwang YS, Jeong M, Park JS et al. Interleukin-1β stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells. Oncogene23(39), 6603–6611 (2004).
   PubMed Web of Science ®Google Scholar
• Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res.7(10), 3298–3304 (2001).
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Haruma K, Sumii K et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am. J. Pathol.152(1), 93–100 (1998).
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Takahashi Y, Haruma K et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br. J. Cancer81(4), 647–653 (1999).
   PubMed Web of Science ®Google Scholar
• Trevino JG, Gray MJ, Nawrocki ST et al. Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis9(2), 101–110 (2006).
   PubMedGoogle Scholar
• Leifheit-Nestler M, Conrad G, Heida NM et al. Overexpression of integrin β5 enhances the paracrine properties of circulating angiogenic cells via Src kinase-mediated activation of STAT3. Arterioscler. Thromb. Vasc. Biol.30(7), 1398–1406 (2010).
   PubMedGoogle Scholar
• Han LY, Landen CN, Trevino JG et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res.66(17), 8633–8639 (2006).
   PubMed Web of Science ®Google Scholar
• Herynk MH, Zhang J, Parikh NU, Gallick GE. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J. Exp. Ther. Oncol.6(3), 205–217 (2007).
   PubMedGoogle Scholar
• Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp. Cell Res.291(1), 70–82 (2003).
   PubMedGoogle Scholar
• Niu G, Wright KL, Huang M et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21(13), 2000–2008 (2002).
   PubMed Web of Science ®Google Scholar
• Roche S, Fumagalli S, Courtneidge SA. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science269(5230), 1567–1569 (1995).
   PubMed Web of Science ®Google Scholar
• Navarra M, Celano M, Maiuolo J et al. Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells. BMC Cancer10, 602 (2010).
   PubMed Web of Science ®Google Scholar
• Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol. Cancer Ther.9(8), 2322–2332 (2010).
   PubMed Web of Science ®Google Scholar
• Ma JG, Huang H, Chen SM et al. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1302-4 (2010) (Epub ahead of print).
   Google Scholar
• Jones RJ, Young O, Renshaw L et al. Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Res. Treat.114(2), 211–221 (2009).
   PubMedGoogle Scholar
• Wadhawan A, Smith C, Nicholson RI, Barrett-Lee P, Hiscox S. Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention. Cancer Treat. Rev.37(3), 234–241 (2011).
   PubMedGoogle Scholar
• Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol.19, 207–235 (2003).
   PubMed Web of Science ®Google Scholar
• Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol. Cell Biol. Res. Commun.2(2), 77–85 (1999).
   PubMedGoogle Scholar
• Mao Q, Zheng X, Yang K et al. Suppression of migration and invasion of PC3 prostate cancer cell line via activating E-cadherin expression by small activating RNA. Cancer Invest.28(10), 1013–1018 (2010).
   PubMed Web of Science ®Google Scholar
• Reynolds AB, Daniel JM, Mo YY, Wu J, Zhang Z. The novel catenin p120cas binds classical cadherins and induces an unusual morphological phenotype in NIH3T3 fibroblasts. Exp. Cell Res.225(2), 328–337 (1996).
   PubMedGoogle Scholar
• Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of β-catenin and its nuclear signaling. Cancer Res.66(4), 2279–2286 (2006).
   PubMed Web of Science ®Google Scholar
• Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr. Opin. Cell Biol.17(5), 459–465 (2005).
   PubMed Web of Science ®Google Scholar
• Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J. Biol. Chem.274(51), 36734–36740 (1999).
   PubMed Web of Science ®Google Scholar
• Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res.8(7), 2430–2436 (2002).
   PubMed Web of Science ®Google Scholar
• Sarrio D, Perez-Mies B, Hardisson D et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene23(19), 3272–3283 (2004).
   PubMed Web of Science ®Google Scholar
• Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin. Exp. Metastasis24(3), 157–167 (2007).
   PubMedGoogle Scholar
• Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res.68(18), 7247–7249 (2008).
   PubMed Web of Science ®Google Scholar
• Rivat C, Le Floch N, Sabbah M et al. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J.17(12), 1721–1723 (2003).
   PubMed Web of Science ®Google Scholar
• Hsia DA, Mitra SK, Hauck CR et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol.160(5), 753–767 (2003).
   PubMed Web of Science ®Google Scholar
• Van Slambrouck S, Jenkins AR, Romero AE, Steelant WF. Reorganization of the integrin α2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int. J. Oncol.34(6), 1717–1726 (2009).
   PubMedGoogle Scholar
• Boyer B, Bourgeois Y, Poupon MF. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene21(15), 2347–2356 (2002).
   PubMed Web of Science ®Google Scholar
• Masaki T, Igarashi K, Tokuda M et al. pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer39(10), 1447–1455 (2003).
   PubMed Web of Science ®Google Scholar
• Wiener JR, Windham TC, Estrella VC et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol. Oncol.88(1), 73–79 (2003).
   PubMed Web of Science ®Google Scholar
• Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer94(2), 344–351 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang XHF, Wang Q, Gerald W et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell16(1), 67–78 (2009).
   PubMed Web of Science ®Google Scholar
• Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res.15(10), 3540–3549 (2009).
   PubMed Web of Science ®Google Scholar
• Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem. Biophys. Res. Commun.341(1), 73–81 (2006).
   PubMed Web of Science ®Google Scholar
• Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat.97(3), 263–274 (2006).
   PubMedGoogle Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res.11(19 Pt 1), 6924–6932 (2005).
   PubMed Web of Science ®Google Scholar
• Shor AC, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res.67(6), 2800–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res.65(20), 9185–9189 (2005).
   PubMed Web of Science ®Google Scholar
• Dong M, Rice L, Lepler S, Pampo C, Siemann DW. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Res.30(11), 4405–4413 (2010).
   PubMedGoogle Scholar
• Ischenko I, Guba M, Yezhelyev M et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis10(3), 167–182 (2007).
   PubMedGoogle Scholar
• Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res.68(9), 3323–3333 (2008).
   PubMed Web of Science ®Google Scholar
• Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin. Cancer Res.15(10), 3416–3422 (2009).
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Castoria G, Auricchio F. Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic implications. Int. J. Biochem. Cell Biol.39(7–8), 1343–1348 (2007).
   PubMedGoogle Scholar
• Migliaccio A, Di Domenico M, Castoria G et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res.65(22), 10585–10593 (2005).
   PubMed Web of Science ®Google Scholar
• Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl Acad. Sci. USA99(23), 14783–14788 (2002).
   PubMed Web of Science ®Google Scholar
• Li Y, Wang JP, Santen RJ et al. Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology151(11), 5146–5156 (2010).
   PubMedGoogle Scholar
• Chakravarty D, Nair SS, Santhamma B et al. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res.70(10), 4092–4101 (2010).
   PubMedGoogle Scholar
• Varricchio L, Migliaccio A, Castoria G et al. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor α tyrosine-phosphorylated peptide. Mol. Cancer Res.5(11), 1213–1221 (2007).
   PubMed Web of Science ®Google Scholar
• Feng W, Webb P, Nguyen P et al. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol. Endocrinol.15(1), 32–45 (2001).
   PubMedGoogle Scholar
• Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. J. Biol. Chem.276(13), 9817–9824 (2001).
   PubMed Web of Science ®Google Scholar
• Shah YM, Rowan BG. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (α) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol.19(3), 732–748 (2005).
   PubMedGoogle Scholar
• Morgan L, Gee J, Pumford S et al. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol. Ther.8(16), 1550–1558 (2009).
   PubMed Web of Science ®Google Scholar
• Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett.238(1), 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Wong WP, Tiano JP, Liu S et al. Extranuclear estrogen receptor-α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc. Natl Acad. Sci. USA107(29), 13057–13062 (2010).
   PubMedGoogle Scholar
• Migliaccio A, Di Domenico M, Castoria G et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol–receptor complex in MCF-7 cells. EMBO J.15(6), 1292–1300 (1996).
   PubMed Web of Science ®Google Scholar
• Castoria G, Migliaccio A, Bilancio A et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J.20(21), 6050–6059 (2001).
   PubMed Web of Science ®Google Scholar
• Wessler S, Otto C, Wilck N, Stangl V, Fritzemeier KH. Identification of estrogen receptor ligands leading to activation of non-genomic signaling pathways while exhibiting only weak transcriptional activity. J. Steroid Biochem. Mol. Biol.98(1), 25–35 (2006).
   PubMedGoogle Scholar
• Castoria G, Barone MV, Di Domenico M et al. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J.18(9), 2500–2510 (1999).
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Castoria G, Di Domenico M et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J.19(20), 5406–5417 (2000).
   PubMed Web of Science ®Google Scholar
• Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids74(7), 586–594 (2009).
   PubMed Web of Science ®Google Scholar
• Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J. Mammary Gland Biol. Neoplasia14(1), 67–78 (2009).
   PubMed Web of Science ®Google Scholar
• Chu I, Sun J, Arnaout A et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell128(2), 281–294 (2007).
   PubMed Web of Science ®Google Scholar
• Hiscox S, Jordan N, Morgan L et al. Adverse features of acquired antihormone resistance and their targeting. In: Therapeutic Resistance to Anti-Hormononal Drugs in Breast Cancer. Hiscox S (Ed.). Springer Publishing, London, UK, 139–159 (2009).
   Google Scholar
• Visram H, Greer PA. 17β-estradiol and tamoxifen stimulate rapid and transient ERK activationin MCF-7 cells via distinct signaling mechanisms. Cancer Biol. Ther.5(12), 1677–1682 (2006).
   PubMed Web of Science ®Google Scholar
• Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr. Relat. Cancer13(Suppl. 1), S77–S88 (2006).
   Google Scholar
• Acconcia F, Barnes CJ, Kumar R. Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology147(3), 1203–1212 (2006).
   PubMedGoogle Scholar
• Zhao Y, Planas-Silva MD. Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity. Cancer Lett.275(2), 204–212 (2009).
   PubMed Web of Science ®Google Scholar
• Santen RJ, Song RX, Zhang Z et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer12(Suppl. 1), S61–S73 (2005).
   PubMed Web of Science ®Google Scholar
• Vallabhaneni S, Nair BC, Cortez V et al. Significance of ER–Src axis in hormonal therapy resistance. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1312-2 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Herynk MH, Beyer AR, Cui Y et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol. Cancer Ther.5(12), 3023–3031 (2006).
   PubMed Web of Science ®Google Scholar
• Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother. Pharmacol.60(4), 535–543 (2007).
   PubMedGoogle Scholar
• Yan SC, Liu YP, Zhang LY et al. Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals. Acta Oncol. DOI: 10.3109/0284186X.2010.543144 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Chen Y, Guggisberg N, Jorda M et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin. Cancer Res.15(10), 3396–3405 (2009).
   PubMed Web of Science ®Google Scholar
• Mendiratta P, Mostaghel E, Guinney J et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol.27(12), 2022–2029 (2009).
   PubMedGoogle Scholar
• Verbeek BS, Vroom TM, Adriaansen-Slot SS et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol.180(4), 383–388 (1996).
   PubMed Web of Science ®Google Scholar
• Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, Bohmer FD. Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J. Cancer Res. Clin. Oncol.127(4), 226–230 (2001).
   PubMed Web of Science ®Google Scholar
• Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res.52(17), 4773–4778 (1992).
   PubMed Web of Science ®Google Scholar
• Wilson GR, Cramer A, Welman A et al. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br. J. Cancer95(10), 1410–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature439(7074), 353–357 (2006).
   PubMed Web of Science ®Google Scholar
• Luttrell DK, Lee A, Lansing TJ et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl Acad. Sci. USA91(1), 83–87 (1994).
   PubMed Web of Science ®Google Scholar
• Muthuswamy SK, Muller WJ. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene11(9), 1801–1810 (1995).
   PubMedGoogle Scholar
• Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene26(24), 3503–3510 (2007).
   PubMed Web of Science ®Google Scholar
• Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell6(3), 209–214 (2004).
   PubMed Web of Science ®Google Scholar
• Li Y, Ren J, Yu W et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J. Biol. Chem.276(38), 35239–35242 (2001).
   PubMed Web of Science ®Google Scholar
• Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol. Ther.6(4), 481–486 (2007).
   PubMed Web of Science ®Google Scholar
• Yang E, Hu XF, Xing PX. Advances of MUC1 as a target for breast cancer immunotherapy. Histol. Histopathol.22(8), 905–922 (2007).
   PubMed Web of Science ®Google Scholar
• Egan C, Pang A, Durda D, Cheng HC, Wang JH, Fujita DJ. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene18(5), 1227–1237 (1999).
   PubMed Web of Science ®Google Scholar
• Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J. Biol. Chem.275(52), 41439–41446 (2000).
   PubMed Web of Science ®Google Scholar
• Tonks NK, Muthuswamy SK. A brake becomes an accelerator: PTP1B – a new therapeutic target for breast cancer. Cancer Cell11(3), 214–216 (2007).
   PubMed Web of Science ®Google Scholar
• Elsberger B, Tan BA, Mallon EA, Brunton VG, Edwards J. Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. Br. J. Cancer103(12), 1831–1834 (2010).
   PubMedGoogle Scholar
• Lerner EC, Smithgall TE. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat. Struct. Biol.9(5), 365–369 (2002).
   PubMedGoogle Scholar
• Campbell EJ, McDuff E, Tatarov O et al. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br. J. Cancer99(11), 1769–1774 (2008).
   PubMedGoogle Scholar
• Elsberger B, Tan BA, Mitchell TJ et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am. J. Pathol.175(4), 1389–1397 (2009).
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Allen J, Costello GF et al. The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc. Am. Assoc. Can. Res.46, A2537 (2005).
   Google Scholar
• Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem.47(27), 6658–6661 (2004).
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol.25(9), 1035–1044 (2007).
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase I trial. J. Bone Miner. Res.25(3), 463–471 (2010).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Lo Russo P, MacPherson IR et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res.15(19), 6232–6240 (2009).
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Krishnamurthi S, Hewes BA et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a Phase 1 study in patients with advanced malignant solid tumors. J. Clin. Oncol.25(18 Suppl.), 3552 (2007).
   PubMedGoogle Scholar
• Somlo G, Atzori F, Strauss L. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. J. Clin. Oncol.27(43S), 1012 (2009).
   Google Scholar
• Finn RS, Bengala C, Ibrahim N. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res.69(242S), 3118 (2009).
   Web of Science ®Google Scholar
• Mayer E, Baurain J, Sparano J. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. J. Clin. Oncol.27(15S), 1011 (2009).
   Google Scholar
• Campone M, Bondarenko I, Brincat S. Preliminary results of a Phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. Breast Can. Res. Treat.106(S268), 6062 (2007).
   Google Scholar
• Hennequin LF, Allen J, Breed J et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem.49(22), 6465–6488 (2006).
   PubMed Web of Science ®Google Scholar
• Elsberger B, Fullerton R, Zino S et al. Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression. Br. J. Cancer103(6), 899–909 (2010).
   PubMed Web of Science ®Google Scholar
• Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer97(5), 577–581 (2007).
   PubMed Web of Science ®Google Scholar
• Takimoto CH. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Cancer Chemother. Pharmacol.63(4), 703–709 (2009).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353(16), 1734–1736 (2005).
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/’triple-negative’ breast cancer cell lines growing in vitro. Breast Cancer Res. Treat.105(3), 319–326 (2007).
   PubMed Web of Science ®Google Scholar
• Dizdar O, Dede DS, Bulut N, Altundag K. Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res. Treat.107(2), 303 (2008).
   PubMedGoogle Scholar
• Harputluoglu H, Dizdar O, Altundag K. Potential targeted therapy options in the management of basal cell subtype of breast carcinoma. Hum. Pathol.38(12), 1869; author reply 1870 (2007).
   PubMedGoogle Scholar
• Anders CK, Acharya CR, Hsu DS et al. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS ONE3(1), e1373 (2008).
   PubMedGoogle Scholar
• Moulder S, Yan K, Huang F et al. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol. Cancer Ther.9(5), 1120–1127 (2010).
   PubMedGoogle Scholar
• Huang F, Reeves K, Han X et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res.67(5), 2226–2238 (2007).
   PubMed Web of Science ®Google Scholar
• Hiscox S, Green TP, Jordan NJ, Smith C, James M, Nicholson RI. Combination therapy using AZD0530 and tamoxifen prevents anti-hormone resistance in breast cancer cells. Breast Cancer Res. Treat.100, S246 (2006).
   Google Scholar